We suggest that patients with AF or AFL who have stable coronary artery disease should receive antithrombotic therapy selected on the basis of their risk of stroke (aspirin for CHADS<sub>2</sub> = 0 and OAC for CHADS<sub>2</sub> &ge;1). Warfarin is preferred over dabigatran for those at high risk of coronary events. (Recommendation Conditional, Quality Moderate)<br /><br />We suggest that patients with AF or AFL who have <i>experienced ACS</i> or who have <i>undergone PCI</i> should receive antithrombotic therapy selected on the basis of a balanced assessment of their risks of stroke, of recurrent coronary artery events, and of hemorrhage associated with the use of combinations of antithrombotic therapies, which in patients at higher risk of stroke may include aspirin plus clopidogrel plus OAC. (Recommendation Conditional, Quality Low)